What did @drkarlnadolsky actually say?
The core argument here is that testosterone prescribing has exploded over two decades without any matching rise in genuine organic hypogonadism, the only FDA-approved indication for testosterone therapy. He says large trials show only "modest improvements" in men with obesity-related low T, and that those men should address obesity and sleep apnea first. He also calls out direct-to-consumer clinics for spreading misinformation and prescribing testosterone without confirmed low blood levels or proper evaluation.
This is not a fringe position. It tracks closely with concerns raised repeatedly in endocrinology literature and by major professional bodies like the Endocrine Society. The framing is pointed but the underlying argument is grounded in documented clinical and commercial patterns.
Does the science back this up?
Mostly, yes, and the key studies are real and specific. The 12-fold increase figure is supported. A 2013 analysis by Baillargeon et al. in JAMA Internal Medicine documented a roughly 3-fold increase from 2001 to 2011 alone, with other estimates tracking continued growth through the mid-2010s that cumulatively reached the range he describes. The "no matching rise in hypogonadism prevalence" claim is also well-supported in the literature.
The clinical trial data he references most likely points to the Testosterone Trials (TTrials), a coordinated set of seven trials published across 2016 and 2017 in the New England Journal of Medicine and related journals (Snyder et al., 2016). Those trials showed modest improvements in sexual function and some mood measures in symptomatic older men with low testosterone, but benefits were not dramatic or universal. For obesity-related hypogonadism specifically, the evidence strongly favors treating the root cause first, a position consistent with current Endocrine Society guidelines.
The JCEM study on clinic websites is also a real category of research. Gabrielson et al. (2019, Journal of Clinical Endocrinology and Metabolism) reviewed direct-to-consumer testosterone clinic websites and found significant inaccuracies in how hypogonadism was defined and how testosterone benefits were presented.
What did they get wrong (or right)?
He got the broad strokes right, but there is one area worth pushing back on. Calling organic hypogonadism "the only approved reason to prescribe testosterone" is technically accurate for FDA labeling, but it flattens a genuinely contested clinical space. The Endocrine Society's 2018 guidelines do allow for testosterone therapy in men with consistently low levels and symptoms, even when a clear organic cause is not identified, provided other causes are ruled out.
The implication that any testosterone prescribing outside confirmed organic hypogonadism is inherently inappropriate overstates the case slightly. Clinicians have legitimate clinical discretion, and the science on symptom-driven prescribing in middle-aged men is still being worked out. That said, his central point about commercial clinics operating outside responsible clinical practice is well-documented and the criticism is fair.
He also does not distinguish between different testosterone formulations or delivery methods, which vary in evidence quality, side effect profiles, and appropriate use cases. That omission is not misleading, but it is a simplification in a complex space.
What should you actually know?
If you are considering testosterone therapy, the starting point is two separate morning blood draws confirming low total testosterone, not a symptom checklist or a clinic's online quiz. Symptoms like fatigue, low libido, and mood changes overlap with dozens of other conditions, including thyroid dysfunction, depression, sleep disorders, and metabolic syndrome.
Obesity itself suppresses testosterone through increased aromatase activity, meaning weight loss can restore normal levels without any exogenous hormone. The same applies to untreated obstructive sleep apnea. A responsible prescriber will evaluate and treat those conditions before reaching for a prescription pad.
The commercial expansion of men's health telehealth is real, and so are the financial incentives he describes. That does not make every telehealth testosterone prescription wrong, but it does mean patients should ask harder questions about how their diagnosis was made, whether confirmatory testing was done, and whether non-hormonal causes were ruled out first.